Clinical trials
Solid Tumor Cancer clinical trials
Below are recruiting solid tumor cancer clinical trials, each written for real people, not researchers. We’re tracking 1,444 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07317505RecruitingPhase 1
Study of JMT108 for Advanced Solid Tumors
This trial tests a new drug called JMT108 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to see if the drug is safe and how it affects the body.
Huntersville, North CarolinaAges 18 years+ - NCT06707610RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called ALK202 for people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and to find the best dose.
Margate, FloridaAges 18–75 - NCT07312903RecruitingPhase 1
Study of DPTX3186 for advanced solid tumors with Wnt pathway activation
This trial tests an experimental oral drug (DPTX3186) for people with advanced solid tumors that are linked to the Wnt pathway. It may be an option if standard treatments are no longer available.
San Antonio, TexasAges 18 years+ - NCT07309770RecruitingPhase 2
Trastuzumab Rezetecan for advanced solid tumors that have stopped responding to standard treatments
This trial tests a new drug called Trastuzumab Rezetecan in people with advanced solid tumors that are HER2-positive and have not responded to standard therapies. It includes three specific groups: people with extramammary Paget's disease, rare solid tumors, or urothelial carcinoma. The goal is to see if this drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07300150RecruitingPhase 1
PT0511 for KRAS-mutated or amplified advanced solid tumors
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
Boston, MassachusettsAges 18 years+ - NCT07303387RecruitingPhase 2
Valemetostat for solid tumors with SWI/SNF gene changes
This trial tests a new drug, valemetostat, for solid tumors that have specific genetic changes (like loss of SMARCB1, SMARCA4, or ARID1A). It is for people whose cancer has continued to grow despite other treatments. The study will see if valemetostat can help shrink or slow tumors.
Villejuif, Val de MarneAges 18 years+ - NCT07288359RecruitingPhase 1/Phase 2
Study of GVV858 for HR+/HER2- breast cancer and other solid tumors
This trial is testing a new drug, GVV858, either alone or with hormone therapy, for people with HR+/HER2- advanced breast cancer or certain other advanced solid tumors. It may be an option if standard treatments are no longer working or available.
Atlanta, GeorgiaAges 18 years+ - NCT07288957RecruitingPhase 1
Testing ABSK131 for advanced solid tumors with a specific genetic change
This trial tests a new drug called ABSK131 in people whose cancer has a missing MTAP gene. It is for advanced solid tumors that have not responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07290088RecruitingPhase 2/Phase 3
Testing a new drug for advanced solid tumors
This trial tests a new drug called PRL3-zumab for people with advanced solid tumors (cancers that have spread). The goal is to see if it can shrink tumors or slow their growth. It is an option for patients who have had limited prior treatments.
Kota BharuAges 18–75 - NCT06883539RecruitingPhase 1
Study of LXP1788 for advanced solid tumors
This trial tests a new drug called LXP1788 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how it affects the body.
TaichungAges 18 years+ - NCT07275242RecruitingPhase 1
Study of SHR-A1811 injection for solid tumors
This study tests an experimental drug called SHR-A1811 given as a shot under the skin (subcutaneous injection) for people with solid tumors. It aims to see if the drug is safe and how well it works.
Guangzhou, GuangdongAges 18 years+ - NCT07274085RecruitingPhase 1
Study of HDM2017 for advanced solid tumors
This trial tests a new drug called HDM2017 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07274852RecruitingPhase 1
Study of a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
Chengdu, SichuanAges 18 years+ - NCT07269899RecruitingPhase 1
A study of WTX212A with or without radiation for advanced cancer
This trial tests a new drug (WTX212A) alone or with radiation therapy for people with advanced solid tumors. It aims to see if the treatment is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT06150365RecruitingEarly Phase 1
Personalized T-cell therapy for advanced solid tumors (KSX01-TCRT)
This study tests a personalized treatment made from your own immune cells (T cells) that are re-engineered to recognize and attack your specific tumor. It is for people with advanced solid tumors that have not responded to other treatments. If you qualify, you will have a blood draw and a tumor sample collected to create your own custom T cell therapy.
BeijingAges 18–70 - NCT06716619RecruitingPhase 1
Immune cell therapy for advanced solid tumors
This trial tests a new immune cell treatment made from your own lymph nodes for advanced solid tumors that haven't responded to standard therapies or have no good treatment options. It aims to see if this personalized cell therapy is safe and can help shrink tumors.
Guangzhou, GaungdongAges 18–75 - NCT07262619RecruitingPhase 1/Phase 2
Study of EIK1005 for advanced solid tumors
This study tests an experimental drug called EIK1005, either alone or combined with another drug (pembrolizumab), for people with advanced solid tumors, especially those with MSI-H or dMMR cancers (tumors that have trouble repairing their DNA). The goal is to see if it can shrink tumors or slow cancer growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07268040RecruitingPhase 2
Study of SHR-7787 injection plus other cancer drugs for solid tumors
This trial is testing a new drug, SHR-7787, combined with other cancer treatments for people with advanced solid tumors that cannot be removed by surgery. The goal is to see if this combination can help shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT07259590RecruitingPhase 1/Phase 2
GFH375 with cetuximab or chemo for KRAS G12D cancers
This trial tests a new drug called GFH375 combined with either cetuximab or chemotherapy for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It's for those whose cancer has worsened after other treatments or who can't have standard therapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07265622RecruitingPhase 1/Phase 2
Study of 7MW4911 for advanced solid tumors
This trial tests a new drug called 7MW4911 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and may be an option if you have a tumor that expresses a certain protein (CDH17).
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07265921RecruitingPhase 1
Study of SIM0609 for advanced solid tumors
This trial tests an investigational new drug, SIM0609, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see early signs that it might help slow or shrink tumors.
BeijingAges 18 years+ - NCT06897228RecruitingPhase 1
NK cell injection with chemo after solid tumor surgery
This trial tests an experimental NK cell therapy (PANK-003) given along with standard chemotherapy after surgery for solid tumors. The goal is to see if adding these immune cells can help prevent the cancer from coming back.
Anyang, HenanAges 18–75 - NCT07264803RecruitingPhase 2
Tumor testing to guide treatment for advanced cancers
This trial uses a patient's own tumor tissue to test which drugs might work best for cancers that have returned or not responded to previous treatments. It focuses on advanced gastric cancer and other solid tumors.
Jinan, ShandongAges 18–75 - NCT07268066Recruiting
Study on DNA patterns in brain, thyroid, and uterine cancers
This trial uses a special test called the methylome to study DNA changes in three types of solid tumors: gliomas (brain tumors), malignant thyroid neoplasms, and endometrial carcinomas (uterine cancer). It aims to better understand these cancers to improve diagnosis and treatment.
Bologna, BOAges 18 years+
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor cancer?
- Yes. Clin2 currently lists 1,444 recruiting solid tumor cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.